2m 2m 2m 2m 2m 2m 2m
- $70.1MMarket Cap
- N/A1-Year Change
- BiotechnologyIndustry
MINDWALK HLDG (HYFT)
Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It
The AI drug discovery field is shifting focus from building the most powerful models to establishing trustworthy, connected biological data foundations. MindWalk Holdings (HYFT) has positioned itself as a leader in this 'context layer' approach with its ReefIQ and LensAI platforms, reporting 52% YoY revenue growth and its first recurring platform contract. The article examines how this represents a maturation of the sector beyond initial hype, comparing MindWalk's strategy to peers like Absci, Recursion, Schrödinger, and Certara.
06/16/2026, 8:45 AM • Benzinga
Peers
Statistics
MoreInformation as of 06/23/2026
Company Profile
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.
Key Executives
- Richard Scott Areglado
- Jennifer Lynne Bath
- Kari Graber
- Shuji Sato
- Thomas Lynch
Current Ownership Distribution
- Other31.9M (68.21%)
- Institutions13.3M (28.48%)
- Insiders1.4M (3.06%)
- Mutual Funds116,134 (0.25%)